Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases
<p>Introduction</p> <p>Antisense oligonucleotides (ASOs) represent a class of drugs which can be rationally designed to complement the coding or non-coding regions of target RNA transcripts. They could modulate pre-messenger RNA splicing, induce mRNA knockdown, or block translation...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Taylor and Francis
2020
|